Patents by Inventor John E. Knox

John E. Knox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MCL-1 INHIBITORS
    Publication number: 20230312490
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 5, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • RAS INHIBITORS
    Publication number: 20230303591
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 28, 2023
    Inventors: Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko
  • Ras inhibitors
    Patent number: 11739074
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 29, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, John E. Knox
  • RAS INHIBITORS
    Publication number: 20230234929
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: January 30, 2023
    Publication date: July 27, 2023
    Inventors: Elena S. KOLTUN, James Cregg, Adrian L. Gill, James Aggen, G. Leslie Burnett, Jennifer Pitzen, Andreas Buckl, John E. Knox, Yang Liu
  • RAS INHIBITORS
    Publication number: 20230226186
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
  • Ras inhibitors
    Patent number: 11690915
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: July 4, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: Naing Aay, G. Leslie Burnett, James Cregg, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Andreas Buckl, Bianca Jennifer Lee, David E. Wildes, Meghan A. Rice, Mallika Singh
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • RAS INHIBITORS
    Publication number: 20230106174
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: April 6, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20230100838
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
  • THIADIAZOLYL DERIVATIVES
    Publication number: 20230078112
    Abstract: Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Pol?) activity, in particular inhibit Pol? activity by inhibiting ATP dependent helicase domain activity of Pol?. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Pol? such as cancer, including homologous recombination (HR) deficient cancers.
    Type: Application
    Filed: May 29, 2020
    Publication date: March 16, 2023
    Inventors: Paul A. BARSANTI, Hilary Plake BECK, Melissa FLEURY, John E. KNOX, Ethan DeNardo MCSPADDEN, Brian Thomas JONES, Luisruben P. MARTINEZ, Zhonghua PEI, Chenbo WANG
  • RAS INHIBITORS
    Publication number: 20220396589
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 15, 2022
    Inventors: Andreas BUCKL, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN, Christopher SEMKO
  • MCL-1 INHIBITORS
    Publication number: 20220340535
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: February 9, 2021
    Publication date: October 27, 2022
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • RAS INHIBITORS
    Publication number: 20220105185
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: September 15, 2021
    Publication date: April 7, 2022
    Inventors: Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
  • 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20220106276
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 7, 2022
    Inventors: Muzaffar ALAM, Leah CLEARY, Melissa FLEURY, Zhonghua PEI, Richard STEEL, James SUTTON, John E. KNOX, Zachary E. R. NEWBY
  • Bicyclic heteroaryl compounds and uses thereof
    Patent number: 11168102
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: November 9, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11130759
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 28, 2021
    Assignee: IDEAYA BIOSCIENCE, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11084798
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 10, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
    Patent number: 11046691
    Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: June 29, 2021
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Leah Cleary, Melissa Fleury, Zhonghua Pei, Richard Steel, James Sutton, John E. Knox, Zachary E. R. Newby
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20210139517
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 13, 2021
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • RAS INHIBITORS
    Publication number: 20210130326
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Adrian L. GILL, Elena S. KOLTUN, James CREGG, Andreas BUCKL, Anne V. EDWARDS, Christopher SEMKO, Micah James GLIEDT, John E. KNOX